Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: Oxidative stress-independent and -dependent cytotoxic potentiation

International Journal of Oncology

Volumn 38, Issue 6, 2011, Pages 1731-1739

  Ong, Pei Shi ^a   Chan, Sui Yung ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; As2O3; Glutathione; Reactive oxygen species

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BUTHIONINE SULFOXIMINE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; ASCORBIC ACID; BUTHIONINE SULFOXIMINE; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FIBROBLASTS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; INTRACELLULAR SPACE; OVARIAN NEOPLASMS; OXIDATIVE STRESS; OXIDES;

EID: 79955833044     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.986     Document Type: Article

References (48)

1. Markman M: Pharmaceutical management of ovarian cancer: current status. Drugs 68: 771-789, 2008.
2. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, De Blasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998. (Pubitemid 28509343)
3. Dai J, Weinberg RS, Waxman S and Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277, 1999. (Pubitemid 29019412)
4. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS and Boise LH: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98: 805-813, 2001.
5. Akao Y, Nakagawa Y and Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455: 59-62, 1999. (Pubitemid 29322782)
6. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM and Zheng MH: Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 4: 33-37, 1999.
7. Du YH and Ho PC: Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 47: 481-490, 2001.
8. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61: 5432-5440, 2001.
9. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F and Ferrero E: Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73: 61-73, 2002. (Pubitemid 34548166)
10. Li M, Cai JF and Chiu JF: Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem 87: 29-38, 2002. (Pubitemid 34969145)
11. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N and Yagi K: Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70: 2253-2269, 2002. (Pubitemid 34251296)
12. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K and Arima T: Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 183: 147-153, 2002. (Pubitemid 34628418)
13. Pu YS, Hour TC, Chen J, Huang CY, Guan JY and Lu SH: Cytotoxicity of arsenic trioxide to transitional carcinoma cells. Urology 60: 346-350, 2002. (Pubitemid 34831797)
14. Park HW, Cho HY, Jung WC, Park OJ, Kim K, Im HY, Lee MH, Kang KW and Park K: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 300: 230-235, 2003. (Pubitemid 36042957)
15. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061, 1996.
16. Forman HJ, Zhang H and Rinna A: Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 30: 1-12, 2009.
17. Ralph SJ: Arsenic-based antineoplastic drugs and their mechanisms of action. Met Based Drugs 2008: 260146, 2008.
18. Yang CH, Kuo ML, Chen JC and Chen YC: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 81: 796-799, 1999.
19. Davison K, Côté S, Mader S and Miller WH: Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17: 931-940, 2003. (Pubitemid 36626322)
20. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH and Lee KP: Feasibility correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 8: 3658-3668, 2002. (Pubitemid 35424755)
21. Baker MA, Cerniglia GJ and Zaman A: Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem 190: 360-365, 1990.
22. Mukhopadhyay A, Chan SY, Lim IJ, Phillips DJ and Phan TT: The role of the activin system in keloid pathogenesis. Am J Physiol Cell Physiol 292: C1331-C1338, 2007. (Pubitemid 46631742)
23. Riordan NH, Riordan HD, Meng X, Li Y and Jackson JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 44: 207-213, 1995.
24. Padayatty S, Sun H, Wang Y, Riordan H, Hewitt S, Katz A, Wesley R and Levine M: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140: 533-537, 2004.
25. Peterkofsky B and Prather W: Cytotoxicity of ascorbate and other reducing agents towards cultured fibroblasts as a result of hydrogen peroxide formation. J Cell Physiol 90: 61-70, 1997.
26. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E and Gisslinger H: Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 112: 783-786, 2001.
27. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y and Gordon LI: Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8: 566-572, 2002. (Pubitemid 34193978)
28. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O and Kakizuka A: Effective treatment of advanced solid by the combinationof arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 11: 737-746, 2004. (Pubitemid 39023120)
29. Wu XX, Ogawa O and Kakehi Y: Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. Int J Oncol 24: 1489-1497, 2004.
30. Han YH, Kim SZ, Kim SH and Park WH: Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. Mol Cells 26: 158-164, 2008.
31. Kito M, Akao Y, Ohishi N, Yagi K and Nozawa Y: Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 291: 861-867, 2002. (Pubitemid 34694354)
32. Han YH, Kim SZ, Kim SH and Park WH: Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyl-dithiocarbamate or buthionine sulfoximine. Int J Oncol 33: 205-213, 2008.
33. Franco R, Panayiotidis MI and Cidlowski JA: Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. J Biol Chem 282: 30452-30465, 2007. (Pubitemid 350035221)
34. Han YH, Kim SH, Kim SZ and Park WH: Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels. J Cell Biochem 104: 862-878, 2008.
35. Leslie EM, Haimeur A and Waalkes MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 279: 32700-32708, 2004. (Pubitemid 39014729)
36. Yedjou C, Thuisseu L, Tchounwou C, Gomes M, Howard C and Tchounwou P: Ascorbic acid potentiation of arsenic trioxide anticancer activity against acute promyelocytic leukemia. Arch Drug Inf 2: 59-65, 2009.
37. Biswas S, Zhao X, Mone AP, Mo X, Vargo M, Jarjoura D, Byrd JC and Muthusamy N: Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk Res 34: 925-931, 2010.
38. Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, Musette P, Dubertret L, Degos L, Dombret H and Bachelez H: Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol 121: 881-893, 2003. (Pubitemid 37239135)
39. Sakagami H, Satoh K, Ohata H, Takahashi H, Yoshida H, Iida M, Kuribayashi N, Sakagami T, Momose K and Takeda M: Relationship between ascorbyl radical intensity and apoptosis-inducing activity. Anticancer Res 16: 2635-2644, 1996. (Pubitemid 26388229)
40. Maramag C, Menon M, Malhotra RK and Seethalakshmi L: Effect of vitamin C on androgen independent prostate cancer cells (PC3 and Mat-Ly-Lu) in vitro: involvement of reactive oxygen species-effect on cell number, viability and DNA synthesis. Cancer Biochem Biophys 16: 17-30, 1998. (Pubitemid 128701518)
41. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005. (Pubitemid 41420895)
42. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J and Levine M: Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104: 8749-8754, 2007. (Pubitemid 47175383)
43. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR and Levine M: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105: 11105-11109, 2008.
44. Verrax J and Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47: 32-40, 2009.
45. Sant AT, Cantin AM, Paquette B and Wagner JR: Ascorbate modulation of H(2)O(2) and camptothecin-induced cell death in Jurkat cells. Cancer Chemother Pharmacol 54: 315-321, 2004. (Pubitemid 39304426)
46. Gilloteaux J, Jamison JM, Arnold D, Ervin E, Eckroat L, Docherty JJ, Neal D and Summers JL: Cancer cell necrosis by autoschizis: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. Scanning 20: 564-575, 1998. (Pubitemid 29031300)
47. Gilloteaux J, Jamison JM, Arnold D, Taper HS and Summers JL: Ultrastructural aspects of autoschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. Ultrastruct Pathol 25: 183-192, 2001. (Pubitemid 32607291)
48. Gilloteaux J, Jamison JM, Arnold D, Taper HS, von Gruenigen VE and Summers JL: Microscopic aspects of autoschizic cell death in human ovarian carcinoma (2774) cells following vitamin C, vitamin K3 or vitamin C:K3 treatment. Microsc Microanal 9: 311-329, 2003. (Pubitemid 37084346)